Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Werewolf Therapeutics
Biotech
Werewolf transforms into Ambros via reverse merger
Werewolf’s hunt for strategic alternatives has ended with a deal that positions Ambros to take its lead candidate through to a filing for approval.
Nick Paul Taylor
Aug 21, 2026 9:50am
Werewolf weighs sale or merger as cash reserves whimper
Feb 24, 2026 5:23pm
AIRNA appoints Elevidys architect as CMO—Chutes & Ladders
Apr 18, 2025 8:30am
BioMarin hires ex-Roche leader Hubbard as CCO—Chutes & Ladders
Mar 8, 2024 9:30am
Jazz, Werewolf to howl at the moon in $1.26M biobucks deal
Apr 7, 2022 9:35am
Synthekine snags $108M to drive two candidates into the clinic
Jun 10, 2021 8:00am
